Mianserin and trazodone for cardiac patients with depression. 1988

C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
Department of Cardiology, Guy's Hospital, London, England.

In a placebo controlled double-blind cross-over study, the cardiovascular and antidepressant effects of three weeks' treatment with mianserin (30-80 mg daily) and trazodone (150-400 mg daily) were studied in depressed patients who had co-existant cardiac disease. In 14 of the 16 patients, no haemodynamic deterioration occurred with either drug. Two patients withdrew from the study. One with coronary artery disease, whose concomitant medication included a calcium-antagonist and a beta-adrenoceptor blocker and who developed severe postural hypotension after his first dose of trazodone while the other had an increased frequency of transient cerebral ischaemic attacks with both mianserin and trazodone, but not with placebo. Mianserin and trazodone are comparable for both antidepressant efficacy and paucity of cardiovascular effects. Although unwanted effects were generally mild, the incidence of dizziness was greater in those patients receiving trazodone. Caution is advised, however, when prescribing either drug to patients with transient cerebral ischaemic attacks or those with coronary artery disease receiving medication.

UI MeSH Term Description Entries
D008297 Male Males
D008803 Mianserin A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors. Lerivon,Mianserin Hydrochloride,Mianserin Monohydrochloride,Org GB 94,Tolvon,Hydrochloride, Mianserin,Monohydrochloride, Mianserin
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1987, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1984, Psychopathology,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 2022, Journal of clinical psychopharmacology,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1984, Current medical research and opinion,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1982, The Journal of international medical research,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1989, Clinical neuropharmacology,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1998, European journal of clinical pharmacology,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1982, Minerva psichiatrica,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1983, The Journal of clinical psychiatry,
C Bucknall, and D Brooks, and P V Curry, and P K Bridges, and N Bouras, and S I Ankier
January 1988, Psychopharmacology,
Copied contents to your clipboard!